KR102324869B1 - Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom - Google Patents
Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom Download PDFInfo
- Publication number
- KR102324869B1 KR102324869B1 KR1020180117817A KR20180117817A KR102324869B1 KR 102324869 B1 KR102324869 B1 KR 102324869B1 KR 1020180117817 A KR1020180117817 A KR 1020180117817A KR 20180117817 A KR20180117817 A KR 20180117817A KR 102324869 B1 KR102324869 B1 KR 102324869B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- extract
- formula
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 239000000284 extract Substances 0.000 title abstract description 67
- 241000731396 Pueraria montana var. thomsonii Species 0.000 title 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 34
- 230000037303 wrinkles Effects 0.000 claims abstract description 28
- 239000002537 cosmetic Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 27
- 230000002087 whitening effect Effects 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 24
- 230000037394 skin elasticity Effects 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 18
- 102000008186 Collagen Human genes 0.000 claims abstract description 18
- 229920001436 collagen Polymers 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 11
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 10
- 230000009467 reduction Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000013040 bath agent Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 29
- 210000003491 skin Anatomy 0.000 description 89
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- -1 burns Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 230000036252 glycation Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 230000037319 collagen production Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 229910052751 metal Chemical class 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- MCYJIRFKDCXYCX-YUPZTAPUSA-N COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O Chemical compound COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-YUPZTAPUSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 108010056686 glycosylated collagen Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 description 1
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 description 1
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 description 1
- MCYJIRFKDCXYCX-UHFFFAOYSA-N tectorigenin 7-O-xylosylglucoside Natural products COc1c(OC2OC(COC3OCC(O)C(O)C3O)C(O)C(O)C2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 화장료 조성물, 식품 조성물 또는 의약외품 조성물에 관한 것이다.
본 발명의 조성물은 멜라닌 감소, 항염증, 콜라겐 합성 촉진, 항당화 효과가 우수하여, 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화, 피부 보습 용도로 유용하게 사용될 수 있다. 따라서, 본 발명의 조성물은 피부에 안전하면서도 피부 상태 개선 효과가 우수한 화장료 조성물, 식품 조성물, 의약외품 조성물로 이용될 수 있다.The present invention relates to a pulverized or pulverized extract; Or a compound derived from the extract; relates to a cosmetic composition, food composition or quasi-drug composition comprising as an active ingredient.
The composition of the present invention has excellent melanin reduction, anti-inflammatory, collagen synthesis, and anti-glycosylation effects, and thus can be usefully used for skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant, and skin moisturizing. Therefore, the composition of the present invention can be used as a cosmetic composition, a food composition, and a quasi-drug composition that is safe for the skin and has an excellent skin condition improvement effect.
Description
본 발명은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 화장료 조성물, 식품 조성물 또는 의약외품 조성물에 관한 것이다.The present invention relates to a pulverized or pulverized extract; Or a compound derived from the extract; relates to a cosmetic composition, food composition or quasi-drug composition comprising as an active ingredient.
구체적으로, 상기 물질을 유효성분으로 포함하는 피부 미백용; 피부 트러블 개선용; 피부 탄력 증진 또는 주름 개선용; 항산화용; 또는 피부 보습용 조성물에 관한 것이다. Specifically, for skin whitening containing the substance as an active ingredient; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; Or it relates to a composition for moisturizing the skin.
사람의 피부색은 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께, 인체 내외의 색소 함유 유무 등 여러 요인들에 의해 결정되며, 특히 멜라노사이트에서 타이로시나제(tyrosinase) 등의 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소가 중요하다. 멜라닌은 피부에 존재하여 자외선 등으로부터 신체를 보호하는 중요한 기능을 하지만, 과잉생산될 경우 색소침착 및 피부노화를 촉진하고 피부암 유발에도 주요한 작용을 하는 것으로 알려져 있다.Human skin color is determined by several factors such as melanocyte activity, blood vessel distribution, skin thickness, and the presence or absence of pigments inside and outside the human body. In particular, enzymes such as tyrosinase are The black pigment called melanin, which is produced by action, is important. Melanin exists in the skin and has an important function of protecting the body from ultraviolet rays, but when it is overproduced, it is known that it promotes pigmentation and skin aging and plays a major role in inducing skin cancer.
과도한 멜라닌 색소 침착을 치료 또는 경감시켜주기 위해서, 이전부터 아스코르빈산(ascorbic acid), 코지산, 알부틴(arbutin), 하이드로퀴논(hudroquinone), 글루타치온(glutathione), 타이로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합하여 사용하였다. 그러나, 이들은 불충분한 미백 효과, 피부에 대한 안전성 문제, 화장료에 배합시 안정성 문제 등으로 인해 그 사용이 제한되고 있다.In order to treat or reduce excessive melanin pigmentation, ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione, substances with tyrosinase inhibitory activity from before These were used in combination with cosmetics or pharmaceuticals. However, their use is limited due to insufficient whitening effect, safety problem for skin, stability problem when formulated in cosmetics, and the like.
또한, 최근 환경오염으로 인한 자외선 양의 증가, 서구화된 생활습관, 스트레스 등 피부건강을 위협하는 요인들이 증가하고 있다. 이들은 피부 오염, 건조, 트러블, 피부면역체계 이상 등을 유발하며, 결국 피부염, 거칠음, 급격한 노화 등을 야기한다. In addition, factors that threaten skin health such as an increase in the amount of ultraviolet rays due to environmental pollution, a westernized lifestyle, and stress are increasing recently. These cause skin contamination, dryness, troubles, and abnormal skin immune system, and eventually cause dermatitis, roughness, rapid aging, and the like.
특히, 체내 활성 산소종의 농도를 증가시키고, 이러한 활성 산소종은 세포구성 성분들인 지질, 단백질, 당 및 DNA 등을 공격하여 과산화 반응을 일으킴으로써 피부의 노화를 촉진하는 문제가 있다. 이에 따라, 활성 산소종의 생성을 억제하는 항산화 효과, 이를 통한 항노화(피부 노화 방지) 효과를 가지는 화장료 조성물에 대한 개발이 요구되고 있다.In particular, there is a problem in that the concentration of reactive oxygen species in the body is increased, and these reactive oxygen species attack lipids, proteins, sugars, DNA, etc., which are cellular components, and cause a peroxidation reaction, thereby promoting skin aging. Accordingly, there is a need for development of a cosmetic composition having an antioxidant effect that inhibits the generation of reactive oxygen species and an anti-aging (skin aging prevention) effect through this.
한편, 피부 보호를 위해 화장품을 사용하게 되는데, 계면활성제, 방부제, 향료, 자외선 차단제, 색소 등 다양한 성분들이 피부에 염증이나 뾰루지, 부종 등 각종 트러블을 발생시키는 것으로 알려져 있다(Maibach. H. I., Contact Dermatitis, 6. 369-404, 1980). 또한, 태양으로부터 나오는 자외선에 의해서도 피부 염증이 유발되는 것으로 알려져 있으며, 체내로부터 배출되는 피지, 땀, 화장품 성분 중의 지방산, 단백질 등이 피부에 존재하는 피부 상재균에 의해 독성이 강한 물질로 분해됨으로써 피부 염증이 유발될 수도 있다. On the other hand, cosmetics are used to protect the skin, and various ingredients such as surfactants, preservatives, fragrances, sunscreens, and pigments are known to cause various troubles such as inflammation, pimples, and edema on the skin (Maibach. HI, Contact Dermatitis). , 6. 369-404, 1980). In addition, it is known that skin inflammation is also caused by ultraviolet rays from the sun, and sebum, sweat, fatty acids in cosmetics, proteins, etc. discharged from the body are decomposed into highly toxic substances by the skin flora present on the skin. It may cause inflammation.
염증 반응은 세균과 같은 외부 물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응으로서, 붉어짐, 따끔거림, 화끈거림, 팽윤, 조직의 변화 등의 현상을 유발하여, 인접한 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 한다. 따라서, 염증 유발 요인이 없어지지 않을 경우, 결과적으로 만성 염증이 일어나게 되어 더욱더 심각한 조직의 손상을 가져온다. 이에 따라, 항염증 효과를 통해 피부 트러블을 초기에 억제할 수 있는 화장료 조성물의 개발이 절실하다.Inflammatory reaction is a physiological reaction to protect the living body from invasion of foreign substances such as bacteria and mechanical damage. It can also cause harmful damage to fields. Therefore, if the inflammatory factors are not eliminated, chronic inflammation occurs as a result, resulting in more serious tissue damage. Accordingly, there is an urgent need to develop a cosmetic composition capable of initially suppressing skin troubles through an anti-inflammatory effect.
콜라겐은 피부의 섬유아세포(fibroblast)에서 생성되는 주요 기질 단백질로서, 피부의 기계적 견고성과 조직의 결합력을 유지하고, 세포접착의 지탱, 세포 분화의 유도 등의 기능을 한다. 연령 증가 및 자외선 조사에 의한 광노화에 의해 콜라겐은 감소하며, 콜라겐을 분해하는 콜라게나제 효소 활성으로 콜라겐 감소가 촉진된다. 이는 피부의 주름 형성과도 밀접한 연관이 있다고 알려져 있다. 또한, 콜라겐 및 엘라스틴 섬유는 진피층 내의 수분 보유에 중요한 역할을 하며, 피부 보습을 통해 피부의 탄력을 유지하는데 관여한다고 알려져 있다.Collagen is a major matrix protein produced in fibroblasts of the skin, and functions such as maintaining the mechanical firmness of the skin and tissue bonding, supporting cell adhesion, and inducing cell differentiation. Collagen decreases due to age increase and photoaging by UV irradiation, and collagen reduction is promoted by the activity of collagenase enzyme that decomposes collagen. This is known to be closely related to the formation of wrinkles on the skin. In addition, collagen and elastin fibers play an important role in retaining moisture in the dermal layer, and are known to be involved in maintaining skin elasticity through skin moisturizing.
현재, 피부 탄력 증진 및 주름 개선 화장료로는 레티놀, 아데노신, 클로렐라 추출물 등이 알려져 있다. 레티놀은 콜라겐 합성을 촉진하며 엘라스타제 효소를 저해하는 물질이지만, 불안정하고 피부 적용시 자극, 발진 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 보습 효과가 미미하여 실질적으로 피부 탄력 증진 및 주름 개선 효과를 기대하기가 어렵다고 알려져 있다.Currently, retinol, adenosine, chlorella extract and the like are known as skin elasticity enhancement and wrinkle improvement cosmetics. Retinol promotes collagen synthesis and inhibits the elastase enzyme, but it is unstable and has limited usage due to safety issues such as irritation and rash when applied to the skin. It is known that it is difficult to expect a wrinkle improvement effect.
또한, 신체 내부에서는 단백질이 가지는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 비효소적 반응이 발생하며, 이를 당화(glycation)라고 한다. 당화된 콜라겐은 진피층의 세포 외 기질에서 콜라겐이 적절한 구조를 형성하지 못하도록 함으로써 피부의 탄력을 잃게 하고 주름 생성을 촉진한다. 또한 당화로 인해 생성된 최종당화산물(Advanced glycation endproducts; AGEs)은 갈색 빛을 띠는 물질로써 피부 노화가 진행됨에 따라 진피층 상부에 쌓이고 피부에서 반사되는 반사 빛이 줄어들게 된다. 이에, 최종당화산물은 피부 노화가 진행됨에 따라 그 양이 늘어나게 되고 점차 얼굴빛이 노랗고 칙칙하게 만드는 물질 중 하나로 꼽히고 있다(Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). In addition, in the body, a non-enzymatic reaction in which a simple sugar such as glucose or fructose forms a covalent bond with a protein or fat of a protein occurs, which is called glycation. Glycosylated collagen prevents the collagen from forming an appropriate structure in the extracellular matrix of the dermal layer, thereby causing the skin to lose its elasticity and promote wrinkle formation. In addition, advanced glycation endproducts (AGEs) generated by glycation are brownish substances, and as skin aging progresses, they accumulate on the upper dermis layer and the reflected light reflected from the skin is reduced. Therefore, the amount of final glycation products increases as skin aging progresses, and it is considered as one of the substances that gradually make the face look yellow and dull (Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). .
당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다. Aminoguanidine, Pyridoxamine, Aspirin, etc. are known as substances that inhibit glycation. However, these substances have a limited amount of use due to safety concerns on the skin or are practically effective due to insignificant effects. There is a problem that cannot be expected.
상기와 같은 배경 하에, 본 발명자들은 천연에 존재하는 천연 자원들 중 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화, 및 피부 보습 효과가 우수한 물질에 관하여 연구를 수행하였으며, 분갈 또는 분갈화 추출물, 또는 이로부터 유래된 화합물을 포함하는 조성물이 멜라닌 감소, 항염증, 콜라겐 합성 촉진, 항당화 효과가 있음을 확인함으로써 본 발명을 완성하였다.Under the above background, the present inventors have conducted research on substances having excellent skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant, and skin moisturizing effects among natural resources existing in nature, powder or powder The present invention was completed by confirming that a composition comprising a brown algae extract, or a compound derived therefrom, has the effect of reducing melanin, anti-inflammatory, promoting collagen synthesis, and anti-glycosylation.
본 발명의 목적은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.An object of the present invention is a pulverized or pulverized extract; Or a compound derived from the extract; to provide a cosmetic composition comprising as an active ingredient.
구체적으로, 상기 물질을 유효성분으로 포함하는 피부 미백용; 피부 트러블 개선용; 피부 탄력 증진 또는 주름 개선용; 항산화용; 또는 피부 보습용 화장료 조성물을 제공하는 것이다.Specifically, for skin whitening containing the substance as an active ingredient; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; Or to provide a cosmetic composition for moisturizing the skin.
본 발명의 다른 목적은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is a pulverized or pulverized extract; Or a compound derived from the extract; to provide a food composition comprising as an active ingredient.
본 발명의 또 다른 목적은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.Another object of the present invention is a pulverized or pulverized extract; Or a compound derived from the extract; to provide a quasi-drug composition comprising as an active ingredient.
본 발명의 하나의 양태는 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 화장료 조성물을 제공한다.One aspect of the present invention is a pulverized or pulverized extract; Or a compound derived from the extract; provides a cosmetic composition comprising as an active ingredient.
본 발명에 있어서, "분갈(粉葛)"은 감갈등(Pueraria thomsonii , 甘葛藤)을 의미하며, 구체적으로 감갈등의 덩이 뿌리를 의미한다. 원기둥 모양, 네모뿔 모양 또는 반원기둥 모양이며 길이 12~15cm, 지름 4~8cm이다. 바깥면은 황백색 또는 엷은 갈색이며 외피를 제거하지 않은 것은 회갈색이며, 단면은 흰색이다. 무겁고 단단하며 자른 면은 분상(粉狀)이고, 종단면은 섬유로 이루어진 세로줄 무늬가 여러줄 있다. 한방에서는 소화불량, 두통, 빈혈, 이질, 복통, 술독, 감기, 구토와 하혈 등의 치료에 쓰이고 있다.In the present invention, "Bungal (粉葛)" is Gamgaldeung ( Pueraria) thomsonii ,甘葛藤), and specifically refers to the tuberous root of persimmon. It is cylindrical, quadrangular, or semi-cylindrical, and has a length of 12-15 cm and a diameter of 4-8 cm. The outer surface is yellowish white or light brown, and the uncoated ones are grayish brown, and the cross section is white. It is heavy and hard, and the cut side is powdery, and the longitudinal cross section has several vertical stripes made of fibers. In oriental medicine, it is used to treat indigestion, headache, anemia, dysentery, abdominal pain, alcohol poisoning, cold, vomiting and bleeding.
본 발명에 있어서, "분갈화(粉葛花)"는 분갈의 꽃 부위를 의미하며, 구체적으로 꽃봉오리 또는 막 피기 시작한 꽃을 의미한다. 한방에서는 주로 하혈 치료에 쓰여왔으며, 독특한 단맛이 있어 술독을 풀어 주고 장을 튼튼하게 한다. In the present invention, "Bungalhwa (粉葛花)" refers to a flower part of a branch, specifically, a flower bud or a flower just starting to bloom. In oriental medicine, it has been mainly used to treat bleeding, and has a unique sweet taste that relieves alcohol poisoning and strengthens the intestines.
본 발명에서 분갈 또는 분갈화는 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있다.In the present invention, pulverization or pulverization may be purchased and used commercially sold, or harvested or cultivated in nature may be used.
본 발명에 있어서, "추출물"은 분갈 또는 분갈화의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 상기 추출물은 분갈 또는 분갈화의 천연, 잡종 또는 변종 식물로부터 추출될 수 있고, 식물 조직 배양물로부터도 추출이 가능하다.In the present invention, "extract" is an extract obtained by pulverization or pulverization extraction treatment, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a prepared or purified product of the extract, or a mixture thereof, etc. It includes extracts of all formulations that can be formed using the extract itself and the extract. The extract may be extracted from pulverized or pricked natural, hybrid or varietal plants, and may also be extracted from plant tissue cultures.
본 발명에서 분갈 또는 분갈화 추출물을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 포함하며, 이들을 단독으로 수행하거나 2종 이상의 방법을 병용하여 수행할 수 있으나, 이에 제한되지 않는다.The method of extracting the pulverized or pulverized extract in the present invention is not particularly limited, and may be extracted according to a method commonly used in the art. It includes hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, and the like, and may be performed alone or in combination of two or more methods, but is not limited thereto.
본 발명에서 추출에 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술분야에서 공지된 임의의 용매를 사용할 수 있다. 추출 용매로는 물(또는 증류수); 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 탄소수 1 내지 4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으나, 이에 제한되지 않는다. 또한, 상기 용매를 사용하여 분갈 또는 분갈화를 1회 이상 추출하여 용매 추출물을 제조할 수 있고, 상기 용매 추출물을 감압 증류한 후 동결건조 또는 분무 건조하여 얻은 건조 추출물을 제조할 수 있다. The type of extraction solvent used for extraction in the present invention is not particularly limited, and any solvent known in the art may be used. As the extraction solvent, water (or distilled water); lower alcohols having 1 to 4 carbon atoms, such as methanol, ethanol, propyl alcohol, and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof may be used, but is not limited thereto. In addition, a solvent extract may be prepared by extracting pulverization or pulverization one or more times using the solvent, and a dry extract obtained by distilling the solvent extract under reduced pressure and then freeze-drying or spray-drying may be prepared.
본 발명의 일 실시예에서는 물(또는 증류수)을 사용하여 분갈 및 분갈화 추출물을 제조한 후 이의 피부 개선 효능을 확인하였다.In an embodiment of the present invention, the skin improvement effect was confirmed after preparing a powdered powder and a powdered extract using water (or distilled water).
본 발명에서 분갈 또는 분갈화 추출물은 이의 분획물, 이의 가공물, 이를 포함하는 동·식물, 이의 추출물의 형태로 포함될 수 있다.In the present invention, the pulverized or pulverized extract may be included in the form of a fraction thereof, a processed product thereof, animals/plants containing the same, and an extract thereof.
본 발명에 있어서, "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다. In the present invention, "fraction" refers to a result obtained by performing fractionation in order to separate a specific component or a specific component group from a mixture containing various components.
본 발명에서 분획물을 얻는 분획 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 수행될 수 있다. 상기 분획 방법의 비제한적인 예로는, 분갈 또는 분갈화를 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법이 있으나, 이에 제한되지 않는다. The fractionation method for obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include, but are not limited to, a method of obtaining a fraction from the extract by treating an extract obtained by extracting pulverization or pulverization with a predetermined solvent.
상기 분획에 사용되는 용매의 종류는 특별히 제한되지 아니하며, 당해 기술분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매로는 물, 알코올 등의 극성 용매; 헥산(Hexane), 에틸아세테이트(Ethyl acetate), 클로로포름(Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매를 사용할 수 있고, 이들을 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있으나, 이에 제한되지 않는다. The kind of solvent used for the fraction is not particularly limited, and any solvent known in the art may be used. Examples of the fractionation solvent include polar solvents such as water and alcohol; A non-polar solvent such as hexane, ethyl acetate, chloroform, and dichloromethane may be used, and these may be used alone or in combination of two or more, but is not limited thereto.
구체적으로, 본 발명에서 분갈 또는 분갈화 추출물로부터 유래된 화합물은 하기 화학식 1 내지 화학식 3으로 표시되는 화합물 중 1종일 수 있다. Specifically, in the present invention, the compound derived from the pulverized or pulverized extract may be one of the compounds represented by the following Chemical Formulas 1 to 3.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
[화학식 3][Formula 3]
화학식 1로 표시되는 화합물은 텍토리게닌 7-O-자일로실글루코사이드(tectorigenin 7-O-xylosylglucoside)로서, 분자식이 C27H30O15이고 분자량이 594.5인 화합물이다. 화학식 2로 표시되는 화합물은 텍토리딘(tectoridin)으로서, 분자식이 C22H22O11이고 분자량이 462.4인 화합물이다. 화학식 3으로 표시되는 화합물은 텍토리게닌(tectorigenin)으로서, 분자식이 C16H12O6이고 분자량이 300.26인 화합물이다.The compound represented by Formula 1 is tectorigenin 7-O-xylosylglucoside, a compound having a molecular formula of C 27 H 30 O 15 and a molecular weight of 594.5. The compound represented by Formula 2 is tectoridin, a compound having a molecular formula of C 22 H 22 O 11 and a molecular weight of 462.4. The compound represented by Formula 3 is tectorigenin, a compound having a molecular formula of C 16 H 12 O 6 and a molecular weight of 300.26.
상기 화합물 3종은 이소플라보노이드계 화합물의 일종으로서, 분갈 또는 분갈화 추출물로부터 수득할 수 있음이 알려져 있다. It is known that the three kinds of compounds are a kind of isoflavonoid-based compounds, and can be obtained from pulverized or pulverized extracts.
본 발명에서 상기 화합물의 수득 경로는 특별히 제한되지 않으며, 해당 기술분야에 공지된 방법으로 화학적으로 합성하거나, 분갈 또는 분갈화 추출물, 또는 다른 종류의 천연물로부터 분리하거나, 시판되는 물질을 구입하여 사용할 수 있다. In the present invention, the route of obtaining the compound is not particularly limited, and it can be chemically synthesized by a method known in the art, separated from a pulverized or pulverized extract, or other kinds of natural products, or commercially available materials can be purchased and used. have.
구체적으로, 본 발명의 화장료 조성물은 피부 미백용; 피부 트러블 개선용; 피부 탄력 증진 또는 주름 개선용; 항산화용; 또는 피부 보습용일 수 있다. Specifically, the cosmetic composition of the present invention is for skin whitening; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; Or it may be for skin moisturizing.
본 발명에 있어서, "피부 미백"이란 멜라닌 색소의 합성을 저해함으로써 피부톤을 밝히고, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 의미한다. 이러한 미백 효과는 예를 들어, 멜라닌 색소 총량을 감소시킴으로써 달성될 수 있으나, 본 발명이 이러한 작용 기전에 제한되는 것은 아니다.In the present invention, "skin whitening" means to lighten skin tone by inhibiting the synthesis of melanin pigment, and to improve skin hyperpigmentation such as spots or freckles caused by ultraviolet rays, hormones, or heredity. Such a whitening effect may be achieved, for example, by reducing the total amount of melanin pigment, but the present invention is not limited to this mechanism of action.
본 발명에 있어서, "피부 트러블 개선"이란 피부에 트러블이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 트러블을 완화시키는 것을 의미하며, 항염증에 의해 달성될 수 있으나, 본 발명이 이러한 작용 기전에 제한되는 것은 아니다.In the present invention, "improving skin troubles" means inhibiting or inhibiting the generation of troubles on the skin, or alleviating troubles that have already been generated, and can be achieved by anti-inflammatory, but the present invention is based on this mechanism of action. It is not limited.
상기 피부 트러블은 대식세포에서의 과도한 일산화질소 생성으로 인하여 유발된 염증에 의해 발생할 수 있는 피부질환을 의미한다. 염증과 관련된 피부질환이면 그 종류에 관계없이 모두 포함되며, 상기 염증과 관련된 피부질환은 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등을 포함하며, 구체적으로, 피부발진, 여드름, 뾰루지, 주사(빨간 코)일 수 있으나 이에 제한되지 않는다. The skin trouble refers to a skin disease that may be caused by inflammation caused by excessive nitric oxide production in macrophages. All skin diseases related to inflammation are included regardless of the type, and the skin diseases related to inflammation include atopic dermatitis, psoriasis, erythematous disease triggered by radiation, chemicals, burns, acid burns, bullous dermatosis, lichenoid form. type disease, allergic itch, seborrheic eczema, rose acne, pemphigus vulgaris, erythema multiforme, erythema nodosum, balanitis, vulvitis, inflammatory hair loss such as alopecia areata, skin T-cell lymphoma, etc. , skin rash, acne, pimples, rosacea (red nose), but is not limited thereto.
상기 항염증은 피부에서 발병된 염증을 억제하는 것을 의미하며, 이는 과도한 나이트릭 옥사이드(nitric oxide; NO) 생성을 억제함으로써 달성될 수 있다. 특히 본 발명의 조성물은 항염증 효과를 통해서 여드름과 같은 피부 트러블을 개선하는 효과를 가질 수 있다.The anti-inflammatory means suppressing inflammation caused in the skin, which can be achieved by suppressing excessive nitric oxide (NO) production. In particular, the composition of the present invention may have an effect of improving skin troubles such as acne through an anti-inflammatory effect.
본 발명에 있어서, "피부 탄력 증진"이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것을 의미한다. 또한, "주름 개선"이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 의미한다. In the present invention, "enhance skin elasticity" means to alleviate the degree of sagging or sagging skin. In addition, "wrinkle improvement" means suppressing or inhibiting the generation of wrinkles on the skin, or alleviating the wrinkles already formed.
본 발명에 있어서, "항산화"란 세포 내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species)에 의한 세포 산화를 억제하는 것을 의미하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포 손상이 감소하는 것을 포함한다.In the present invention, "antioxidation" means inhibiting cellular oxidation by highly reactive free radicals or reactive oxygen species depending on intracellular metabolism or oxidative stress caused by the influence of ultraviolet rays. and removing free radicals or reactive oxygen species, thereby reducing cell damage.
본 발명에 있어서, "피부 보습"이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과를 높일 경우 피부의 주름 개선, 탄력도 증가에도 이로운 영향을 미칠 수 있다.In the present invention, "moisturizing the skin" means to increase the feeling of moisture in the skin and to maintain a moist state. If you increase the skin moisturizing effect, it can have a beneficial effect on improving wrinkles and increasing elasticity of the skin.
구체적으로, 본 발명의 조성물은 멜라닌 감소 효과, 항염증 효과, 콜라겐 합성 촉진 효과, 항당화 효과를 가지는 것일 수 있다. 본 발명의 일 실시예에서는 분갈 추출물, 분갈화 추출물, 화학식 1 내지 화학식 3으로 표시되는 화합물이 각각 멜라닌 생성을 억제하고, NO 생성을 억제하며, 제1형 콜라겐(type Ⅰ collagen) 합성을 촉진시키고, 항산화 효과 및 항당화 효과가 있어(표 1 내지 표 5), 본 발명의 조성물이 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화 및/또는 피부 보습 용도로 유용하게 사용될 수 있음을 확인하였다.Specifically, the composition of the present invention may have a melanin reduction effect, an anti-inflammatory effect, a collagen synthesis promoting effect, and an anti-glycosylation effect. In an embodiment of the present invention, the powdered extract, the powdered extract, and the compounds represented by Formulas 1 to 3, respectively, inhibit melanin production, inhibit NO production, and promote the synthesis of type I collagen, , there is an antioxidant effect and anti-glycosylation effect (Tables 1 to 5), the composition of the present invention can be usefully used for skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant and / or skin moisturizing purpose Confirmed.
본 발명의 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되지 않는다. The cosmetic composition of the present invention is a solution, external ointment, cream, foam, nutrient lotion, softening lotion, pack, soft water, emulsion, makeup base, essence, soap, liquid detergent, bath agent, sunscreen cream, sun oil, suspension, emulsion It can be prepared in a formulation selected from the group consisting of liquid, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, and spray, but is not limited thereto. .
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되지 않는다. 본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.In addition, the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers to be formulated in general skin cosmetics, and conventional ingredients include, for example, oil, water, surfactant, humectant, lower alcohol, Thickeners, chelating agents, colorants, preservatives, fragrances and the like may be appropriately mixed, but the present invention is not limited thereto. The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures thereof may be used, but are not limited thereto.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component. In particular, in the case of a spray, additional chlorophyll propellants such as, but not limited to, fluorohydrocarbons, propane/butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty ester, fatty acid ester of polyethylene glycol or sorbitan may be used. However, it is not limited thereto.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a suspension, as a carrier component a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used, but is not limited thereto.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionate, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugar, etc. may be used as carrier components. can, but is not limited thereto.
본 발명의 다른 양태는 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 유효성분으로 포함하는 식품 조성물을 제공한다.Another aspect of the present invention is a pulverized or pulverized extract; Or a compound derived from the extract; provides a food composition comprising as an active ingredient.
구체적으로, 본 발명에서 분갈 또는 분갈화 추출물로부터 유래된 화합물은 하기 화학식 1 내지 화학식 3으로 표시되는 화합물 중 1종일 수 있다. Specifically, in the present invention, the compound derived from the pulverized or pulverized extract may be one of the compounds represented by the following Chemical Formulas 1 to 3.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
[화학식 3][Formula 3]
구체적으로, 본 발명의 식품 조성물은 피부 미백용; 피부 트러블 개선용; 피부 탄력 증진 또는 주름 개선용; 항산화용; 또는 피부 보습용일 수 있다. Specifically, the food composition of the present invention is for skin whitening; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; Or it may be for skin moisturizing.
분갈, 분갈화, 화학식 1 내지 화학식 3, 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화, 피부 보습은 상기에서 설명한 바와 같다.Powdering, powdering, Formulas 1 to 3, skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant, and skin moisturizing are the same as described above.
상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되지 않는다. 또한 본 발명의 식품 조성물은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물; 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The food composition may be used in the form of health functional food, but is not limited thereto. In addition, the food composition of the present invention is a powdered or powdered extract; or a compound derived from said extract; In addition, it may include food supplementary additives that are acceptable for food.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 통상의 기술자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 이에 제한되지 않는다.In the present invention, "food supplement additive" means a component that can be added auxiliary to food, it is added to the manufacture of health functional food of each formulation, and can be appropriately selected and used by those skilled in the art. Examples of food supplement additives include various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 상기 건강식품이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 의미한다. 여기서 기능성이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화, 피부 보습 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The food composition of the present invention may include a health functional food. The health food refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and pills using raw materials or ingredients useful for the human body. Here, the term "functionality" refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological effects with respect to the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, if the formulation of the health functional food is also recognized as a health functional food, it may be manufactured without limitation. The food composition of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur during long-term administration of the drug using food as a raw material, and has excellent portability, Health functional food can be taken as a supplement for skin whitening, skin trouble improvement, skin elasticity improvement or wrinkle improvement, antioxidant, and skin moisturizing effect.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.There is no limitation in the form that the health functional food of the present invention can take, and it may include any food in a conventional sense, and may be used interchangeably with terms known in the art, such as functional food. In addition, the health functional food of the present invention can be prepared by mixing known additives with other suitable auxiliary ingredients that may be included in the food according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and There are vitamin complexes and the like, and it can be prepared by adding the extract according to the present invention as a main component to juice, tea, jelly, juice, and the like. It also includes food used as feed for animals.
본 발명의 또 다른 양태는 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물 또는 이의 약학적으로 허용가능한 염;을 유효성분으로 포함하는 의약외품 조성물을 제공한다.Another aspect of the present invention is a powdered or crushed extract; Or a compound derived from the extract or a pharmaceutically acceptable salt thereof; provides a quasi-drug composition comprising as an active ingredient.
구체적으로, 본 발명에서 분갈 또는 분갈화 추출물로부터 유래된 화합물은 하기 화학식 1 내지 화학식 3으로 표시되는 화합물 중 1종일 수 있다. Specifically, in the present invention, the compound derived from the pulverized or pulverized extract may be one of the compounds represented by the following Chemical Formulas 1 to 3.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
[화학식 3][Formula 3]
구체적으로, 본 발명의 의약외품 조성물은 피부 미백용; 피부 트러블 개선용; 피부 탄력 증진 또는 주름 개선용; 항산화용; 또는 피부 보습용일 수 있다. Specifically, the quasi-drug composition of the present invention is for skin whitening; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; Or it may be for skin moisturizing.
분갈, 분갈화, 화학식 1 내지 화학식 3, 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화, 피부 보습은 상기에서 설명한 바와 같다.Powdering, powdering, Formulas 1 to 3, skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant, and skin moisturizing are the same as described above.
본 발명의 의약외품 조성물에는 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물; 이외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다. The quasi-drug composition of the present invention includes powdered or powdered extract; or a compound derived from said extract; In addition, if necessary, it may further include a pharmaceutically acceptable carrier, excipient or diluent. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, and includes, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. may include
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 포함할 수 있으나, 이에 제한되지 않는다. Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia gum, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , injectable esters, Witepsol, Macrogol, Tween 61, cacao butter, laurage, and the like, but are not limited thereto.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention may include, but is not limited to, disinfectant cleaner, shower foam, ointment, wet tissue, coating agent, etc. It may be appropriately selected from the techniques of
또한, 본 발명의 조성물에 포함되는 화학식 1 내지 화학식 3으로 표시되는 화합물은, 화장품학적, 식품학적 또는 약학적으로 허용 가능한 염의 형태로 포함될 수 있다. 이는 양이온과 음이온이 정전기적 인력에 의해 결합하고 있는 물질인 염 중에서도 화장품학적, 식품학적 또는 약학적으로 사용될 수 있는 형태의 염을 의미하는데, 사용자에게 비교적 비독성이고 무해한 유효작용을 갖는 농도로서 이 염에 기인한 부작용이 화합물의 이로운 효능을 저하시키지 않는 임의의 모든 유기 또는 무기부가염을 의미한다. 이러한 염으로는 유리산(free acid)에 의해 형성되는 산부가염 또는 염기에 의해 형성되는 금속염이 있다.In addition, the compounds represented by Chemical Formulas 1 to 3 included in the composition of the present invention may be included in the form of a cosmetically, food, or pharmaceutically acceptable salt. This refers to a salt in a form that can be used cosmetically, food or pharmaceutical among salts, which are substances in which cations and anions are combined by electrostatic attraction. Any and all organic or inorganic addition salts in which the side effects attributable to the salt do not diminish the beneficial efficacy of the compound. Such salts include acid addition salts formed with free acids or metal salts formed with bases.
유리산으로는 유기산과 무기산을 사용할 수 있으며, 유기산으로는 메탄술폰산, p-톨루엔술폰산, 아세트산, 트리플루오로아세트산, 말레산(maleic acid), 숙신산, 옥살산, 벤조산, 타르타르산, 푸마르산(fumaric acid), 만데르산, 프로피온산(propionic acid), 구연산(citric acid), 젖산(lactic acid), 글리콜산(glycollic acid), 글루콘산(gluconic acid), 갈락투론산, 글루탐산, 글루타르산(glutaric acid), 글루쿠론산(glucuronic acid), 아스파르트산, 아스코르브산, 카본산, 바닐릭산, 요오드화수소산(hydroiodic acid) 등을 사용할 수 있고, 무기산으로는 염산, 인산, 황산, 질산, 주석산 등을 사용할 수 있으나, 이에 제한되지 않는다.Organic acids and inorganic acids can be used as free acids, and organic acids include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, and fumaric acid. , manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid , glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc. can be used, and as the inorganic acid, hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc. can be used. , but not limited thereto.
또한, 염기를 사용하여 화장품학적 또는 약학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속염 또는 알칼리 토금속 염은, 예를 들어 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해시키고, 비용해 화합물 염을 여과한 후 여액을 증발, 건조시켜 얻는다. 이때, 금속염으로는 특히 나트륨, 칼륨, 또는 칼슘염을 제조하는 것이 화장품학상 적합하나, 이에 제한되지 않는다. 또한 이에 대응하는 은염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 은염(예, 질산은)과 반응시켜 얻을 수 있다.In addition, a base may be used to prepare a cosmetically or pharmaceutically acceptable metal salt. The alkali metal salt or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. In this case, as the metal salt, it is cosmetically suitable to prepare a sodium, potassium, or calcium salt in particular, but is not limited thereto. Also, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (eg, silver nitrate).
본 발명의 화학식 1 내지 화학식 3으로 표시되는 화합물 또는 이의 염은 수화물, 에탄올화물 등의 형태를 포함하는 용매화된 형태뿐만 아니라 비-용매화된(unsolvated) 형태로 존재할 수도 있다. 또한, 본 발명의 화학식 1 내지 화학식 3으로 표시되는 화합물 또는 이의 염은 결정형 또는 무정형 형태로 존재할 수 있으며, 이러한 모든 물리적 형태는 본 발명의 범위에 포함된다.The compounds represented by Formulas 1 to 3 or a salt thereof of the present invention may exist in unsolvated as well as solvated forms including hydrates and ethanolates. In addition, the compound represented by Formulas 1 to 3 or a salt thereof of the present invention may exist in a crystalline or amorphous form, and all such physical forms are included in the scope of the present invention.
본 발명의 화장료 조성물, 식품 조성물, 의약외품 조성물은 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 추가로 함유할 수 있다. 예컨대, 본 발명이 속한 기술분야에서 공지된 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화 및/또는 피부 보습 성분을 포함할 수 있을 것이다. 상기 추가 성분으로 인해, 본 발명의 조성물의 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화 및/또는 피부 보습 효과는 더욱 증진될 수 있을 것이다. 추가 성분의 함량 범위는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성 등을 고려하여 통상의 기술자가 적절히 조절할 수 있다.The cosmetic composition, food composition, and quasi-drug composition of the present invention may additionally contain one or more active ingredients exhibiting the same or similar functions. For example, it may include skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant and/or skin moisturizing ingredients known in the art to which the present invention pertains. Due to the additional ingredients, the skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant and/or skin moisturizing effect of the composition of the present invention may be further enhanced. The content range of the additional component may be appropriately adjusted by those skilled in the art in consideration of skin safety, ease of formulation, and stability of active ingredients according to combined use.
나아가, 본 발명은 분갈 또는 분갈화 추출물; 또는 상기 추출물로부터 유래된 화합물;을 개체의 피부에 도포하는 단계를 포함하는, 피부 미백; 피부 트러블 개선; 피부 탄력 증진 또는 주름 개선; 항산화; 또는 피부 보습 방법을 제공한다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함할 수 있다.Furthermore, the present invention relates to a pulverized or pulverized extract; or a compound derived from the extract; skin whitening, including applying to the skin of an individual; improvement of skin troubles; increase skin elasticity or improve wrinkles; antioxidant; or a method of moisturizing the skin. The subject may include, without limitation, mammals including rats, livestock, and humans.
본 발명의 조성물은 멜라닌 감소, 항염증, 콜라겐 합성 촉진, 항당화 효과가 우수하여, 피부 미백, 피부 트러블 개선, 피부 탄력 증진 또는 주름 개선, 항산화, 피부 보습 용도로 유용하게 사용될 수 있다. 따라서, 본 발명의 조성물은 피부에 안전하면서도 피부 상태 개선 효과가 우수한 화장료 조성물, 식품 조성물, 의약외품 조성물로 이용될 수 있다.The composition of the present invention has excellent melanin reduction, anti-inflammatory, collagen synthesis promotion, and anti-glycosylation effects, and thus can be usefully used for skin whitening, skin trouble improvement, skin elasticity enhancement or wrinkle improvement, antioxidant, and skin moisturizing. Therefore, the composition of the present invention can be used as a cosmetic composition, a food composition, and a quasi-drug composition that is safe for the skin and has an excellent skin condition improvement effect.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. These examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.
실시예Example 1: 분갈 추출물의 제조 1: Preparation of powdered extract
분갈을 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 분갈 추출물을 제조하였다.After the powder was dried well and chopped, 100 g of dry weight was placed in a flask, and extracted by cooling with 1000 g of an extraction solvent (distilled water) for 3 days. The chilled extract was filtered through a filter having a pore size of 0.2 μm to prepare a powdered extract.
실시예Example 2: 2: 분갈화splitting 추출물의 제조 Preparation of extracts
분갈의 꽃과 꽃봉오리를 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(증류수) 1000g으로 3일간 냉침하여 추출하였다. 냉침된 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과하여 분갈화 추출물을 제조하였다.After the flowers and buds of Bungal were well dried and chopped, 100 g of dry weight was placed in a flask, and extracted by cooling with 1000 g of an extraction solvent (distilled water) for 3 days. The chilled extract was filtered through a filter having a pore size of 0.2 μm to prepare a pulverized extract.
실시예Example 3: 화합물의 준비 3: Preparation of compounds
화합물 1 내지 3의 입수 경로는 특별히 제한되지 않으며, 당업계에 공지된 방법으로 화학적으로 합성하거나 시판되는 물질을 사용하여 실험에 사용할 수 있다.The route of obtaining compounds 1 to 3 is not particularly limited, and may be chemically synthesized by a method known in the art or used in an experiment using commercially available materials.
실험예Experimental example 1: 멜라닌 생성 억제에 따른 미백 효과 1: Whitening effect by inhibiting melanin production
실시예 1 및 실시예 2, 화합물 1 내지 3을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 멜라닌 총량을 측정함으로써 미백 효과를 확인하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980). 실험 전 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도를 선정하여 미백평가를 수행하였다.Examples 1 and 2, compounds 1 to 3 were added to the culture medium of B-16 mouse melanoma cells, and the whitening effect was confirmed by measuring the total amount of melanin at the cell level (Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980). Before the experiment, toxicity was evaluated for melanoma cells in mice, and a non-toxic concentration was selected for whitening evaluation.
배양액에 최종 농도가 10 ppm 또는 100 ppm이 되도록 하였으며, 대조군인 알부틴은 100 ppm이 되도록 배지에 첨가하여 각각 B-16 멜라노마 세포에 처리하여 3일간 배양하였다. 이후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심분리한 후, 멜라닌을 추출하였다. 떼어낸 세포는 수산화나트륨 용액(1N 농도) 1 mL를 첨가하고 10분 동안 끓여 멜라닌을 녹인 후, 분광 광도계를 이용하여 400 nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다.The final concentration of the culture medium was 10 ppm or 100 ppm, and arbutin, a control, was added to the medium to 100 ppm, treated with B-16 melanoma cells, respectively, and cultured for 3 days. Thereafter, the cells were treated with trypsin, removed from the culture vessel, centrifuged, and then melanin was extracted. To the detached cells, 1 mL of sodium hydroxide solution (1N concentration) was added and boiled for 10 minutes to dissolve melanin, and then the amount of generated melanin was measured by measuring the absorbance at 400 nm using a spectrophotometer.
멜라닌 양은 단위 세포수(1×106 cell)의 흡광도를 나타내는 방법으로 측정하였으며, 대조군에 대한 상대적인 멜라닌 총량을 저해율(%)로 계산하고 결과를 표 1에 정리하였다.The amount of melanin was measured by a method indicating the absorbance of the unit cell number (1×10 6 cells), the total amount of melanin relative to the control was calculated as the inhibition rate (%), and the results are summarized in Table 1.
상기 표 1의 결과에서 알 수 있듯이, 분갈 추출물(실시예 1) 및 분갈화 추출물(실시예 2), 화합물 1 내지 3은 모두 저농도에서도 우수한 멜라닌 감소 효과를 나타내어, 피부 미백 용도로 사용할 수 있음을 확인하였다.As can be seen from the results in Table 1, the powdered extract (Example 1), the powdered extract (Example 2), and compounds 1 to 3 all showed excellent melanin reduction effects even at low concentrations, indicating that they could be used for skin whitening purposes. Confirmed.
실험예Experimental example 2 : NO 생성 억제에 따른 항염증 효과 2: Anti-inflammatory effect by inhibiting NO production
실시예 1 및 실시예 2, 화합물 1 내지 3의 항염증 효과 및 피부 트러블 개선 효과를 확인하기 위하여, RAW264.7 세포주(ATCC number: CRL-2278)를 이용한 GRIESS 법으로 나이트릭 옥사이드(nitric oxid: NO) 형성 억제력 실험을 실시하였다.In order to confirm the anti-inflammatory effect and skin trouble improvement effect of Examples 1 and 2 and Compounds 1 to 3, nitric oxide (nitric oxid: NO) formation inhibition test was conducted.
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 24-웰 프레이트에 3×105개씩 넣은 후, 24시간 동안 배양시켰다. 이어서, 최종농도 10 또는 100 ppm의 농도로 희석한 세포 배지로 교체하였다. 이 때, NO 생성 억제 물질인 L-NMMA(L-NG-monomethylarginine)을 양성대조군으로 함께 처리하여 30분 동안 배양하였고, 자극원으로 LPS(lipopolysaccharide)를 1 μg씩 처리하여 24시간 동안 배양하였다. 상층액을 100 μl씩 취해 96-웰 플레이트에 옮기고, GRIESS 용액을 100 μL씩 첨가하여 상온에서 10분간 반응시켰다. 540 nm에서의 흡광도를 측정함으로써 NO 생성 저해율(%)을 계산하고, 그 결과를 하기 표 2에 나타내었다.Specifically, RAW264.7 cells, which are macrophages of mice, were subcultured several times, and then put into a 24-well plate 3×10 5 each, and cultured for 24 hours. Then, it was replaced with a cell medium diluted to a final concentration of 10 or 100 ppm. At this time, the NO production inhibitory substance L-NMMA (L-NG-monomethylarginine) was treated together as a positive control and incubated for 30 minutes, and 1 μg of LPS (lipopolysaccharide) was treated as a stimulus and cultured for 24 hours. 100 μl of the supernatant was taken and transferred to a 96-well plate, 100 μL of GRIESS solution was added and reacted at room temperature for 10 minutes. The NO production inhibition rate (%) was calculated by measuring the absorbance at 540 nm, and the results are shown in Table 2 below.
상기 표 2의 결과에서 알 수 있듯이, 분갈 추출물(실시예 1) 및 분갈화 추출물(실시예 2), 화합물 1 내지 3은 모두 우수한 NO 생성 저해 효과를 나타내어 피부 트러블 개선 용도로 사용할 수 있음을 확인하였다. 또한, 다른 항염 물질과 함께 사용시 상승 효과를 나타낼 것임을 기대할 수 있다.As can be seen from the results of Table 2, it was confirmed that the powdered extract (Example 1), the powdered extract (Example 2), and compounds 1 to 3 all showed excellent NO production inhibitory effects, so that they could be used for improving skin troubles. did. In addition, it can be expected to exhibit a synergistic effect when used together with other anti-inflammatory substances.
실험예Experimental example 3: 인체 유래의 섬유아세포에서 제1형 콜라겐(type Ⅰ collagen) 합성 촉진 효과 3: Effect of promoting the synthesis of type I collagen in human-derived fibroblasts
실시예 1 및 실시예 2, 화합물 1 내지 3을 인간 유래 섬유 아세포의 배양액에 첨가하여 세포 수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type Ⅰ C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 콜라겐 합성량을 측정하기 위해 실시예 1 및 실시예 2, 화합물 1 내지 3을 섬유 아세포의 배양 배지(DMEM 배지)에 첨가하여 48시간 배양한 후, 배양액을 취하여 PICP EIA 키트로 저농도에서 제1형 콜라겐 합성 정도를 분광 광도계를 이용하여 450 nm에서 측정하였다. 효과의 비교를 위하여 시료를 처리하지 않은 섬유 아세포의 배양 배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 μg/mL가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성 증가율(%)은 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 3에 나타내었다.Examples 1 and 2, and compounds 1 to 3 were added to the culture medium of human-derived fibroblasts to confirm the effect of promoting the synthesis of type 1 collagen at the cellular level. The measurement of synthesized collagen was quantified using the PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay KIT). In order to measure the amount of collagen synthesis, Examples 1 and 2, and compounds 1 to 3 were added to the fibroblast culture medium (DMEM medium) and cultured for 48 hours. The degree of collagen synthesis was measured at 450 nm using a spectrophotometer. For comparison of the effect, the collagen synthesis level was measured in the same way for the sample in which the untreated fibroblast culture medium (negative control group) and vitamin C (positive control group) were added to a final concentration of 52.85 μg/mL. The collagen production increase rate (%) was calculated as the ratio of the relative collagen production to the control, and the results are shown in Table 3 below.
상기 표 3의 결과에서 알 수 있듯이, 분갈 추출물(실시예 1) 및 분갈화 추출물(실시예 2), 화합물 1 내지 3은 모두 콜라겐 합성을 촉진시켰으며, 피부 탄력 증진 또는 주름 개선, 피부 보습 용도로 사용할 수 있음을 알 수 있었다. 특히, 화합물 1 내지 3의 경우 양성대조군보다 낮은 농도로 사용하였음에도 불구하고 유사하거나 더욱 우수한 콜라겐 합성 효과를 나타낸다는 것을 확인하였다. As can be seen from the results in Table 3, the powdered extract (Example 1), the powdered extract (Example 2), and compounds 1 to 3 all promoted collagen synthesis, and used to enhance skin elasticity or improve wrinkles, and for skin moisturizing found that it can be used as In particular, it was confirmed that compounds 1 to 3 exhibited similar or superior collagen synthesis effects despite being used at a lower concentration than the positive control group.
실험예Experimental example 4: 자유라디칼 소거에 따른 항산화 효과 4: Antioxidant effect according to free radical scavenging
실시예 1 및 실시예 2, 화합물 1 내지 3의 항산화 작용을 확인하기 위해 자유라디칼 소거 활성을 측정하였다. 자유라디칼 소거 활성은 DPPH를 이용하여 측정하였다. DPPH는 시그마사(Sigma Co., Ltd, 미국)에서 구입하여 사용하였다. 먼저, 1.5 mM(0.06 ㎎/mL)의 표준 DPPH 에탄올 용액을 만들었다. 그리고, 3차 증류수를 이용하여 1000 μg/mL 비타민 C 용액을 만든 다음 1/2씩 연속적으로 희석하여 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625, 0.48828125 μg/mL 농도의 비타민 C 시료를 만들었다. 또한 실시예 1 및 2는 1000000 μg/mL 농도부터, 화학식 1 내지 3은 비타민 C와 동일한 농도로 화합물의 희석액을 준비하였다. 그 다음, 상기 시료와 표준 DPPH 용액을 같은 비율로 첨가하여 잘 교반한 후, 37℃에서 30분간 반응시키고 520 ㎚에서 흡광도를 측정하였다. 자유 라디칼 소거능은 무첨가 대조군의 자유 라디칼을 50% 제거하는데 필요한 비타민 C 및 화학식 1의 화합물의 농도인 IC50을 구하여 그 결과를 하기 표 5에 나타내었다.In order to confirm the antioxidant activity of Examples 1 and 2, and Compounds 1 to 3, free radical scavenging activity was measured. Free radical scavenging activity was measured using DPPH. DPPH was purchased from Sigma Co., Ltd. (USA) and used. First, a standard DPPH ethanol solution of 1.5 mM (0.06 mg/mL) was prepared. Then, make a 1000 μg/mL vitamin C solution using tertiary distilled water, and then serially dilute by 1/2 to 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625, 0.48828125 μg A sample of vitamin C at a concentration of /mL was prepared. In Examples 1 and 2, dilution solutions of the compounds were prepared from 1000000 μg/mL concentrations, and in Formulas 1 to 3, at the same concentration as vitamin C. Then, the sample and the standard DPPH solution were added in the same ratio, stirred well, reacted at 37° C. for 30 minutes, and absorbance was measured at 520 nm. The free radical scavenging ability was obtained by obtaining IC 50 , which is the concentration of vitamin C and the compound of Formula 1 required to remove 50% of free radicals of the non-additive control group, and the results are shown in Table 5 below.
상기 표 4의 결과에서 알 수 있듯이, 분갈 추출물(실시예 1) 및 분갈화 추출물(실시예 2), 화합물 1 내지 3 모두 우수한 자유라디칼 소거 활성을 나타내어 항산화 용도로 사용할 수 있음을 확인하였다. 또한, 피부 미백, 피부 탄력 증진 또는 주름 개선, 피부 보습 용도에 있어서도 다른 물질과 함께 상승 효과를 나타낼 것임을 기대할 수 있다.As can be seen from the results of Table 4, it was confirmed that the powdered extract (Example 1) and the powdered extract (Example 2), and compounds 1 to 3 all exhibit excellent free radical scavenging activity, and thus can be used for antioxidant purposes. In addition, it can be expected that it will exhibit a synergistic effect together with other substances in skin whitening, skin elasticity enhancement or wrinkle improvement, and skin moisturizing use.
실험예Experimental example 5 : 5: 항당화anti-glycosylation (anti-(anti- glycationglycation ) 효과) effect
당화 저해 효능을 확인하기 위하여, L-arginine과 포도당을 이용하여 당화 저해 활성을 측정하였다. In order to confirm the glycation inhibitory effect, the glycation inhibitory activity was measured using L-arginine and glucose.
먼저, 1M 인산 완충액(pH 7.4)을 이용하여 1M L-아르기닌(arginine), 1M 포도당을 녹여 준비하고 1M 인산 완충액을 이용하여 시료를 50 ppm, 100 ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충액을 1 : 4의 비율로 혼합한 다음 96-웰 플레이트에 80 μl씩 분주하였다. 여기에 각각 10 ppm, 100 ppm으로 희석한 시료와 양성대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100 μL씩 첨가하였다. 이 시료들을 잘 섞어준 다음, 마지막으로 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충액으로 희석한 포도당을 첨가하였다. 70℃에서 4시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420 nm에서 흡광도를 측정하여 당화 정도를 측정하였다.First, 1M L-arginine and 1M glucose were dissolved in 1M phosphate buffer (pH 7.4) and prepared by diluting the sample to 50 ppm and 100 ppm using 1M phosphate buffer. 1M L-arginine and 1M phosphate buffer were mixed in a ratio of 1:4, and then 80 μl of each was dispensed to a 96-well plate. Here, 100 μL of a sample diluted to 10 ppm and 100 ppm, respectively, and 0.01 M aminoguanidin to be used as a positive control were added. After mixing these samples well, finally, glucose diluted with 1M phosphate buffer was added so that the final concentration of glucose was 0.1M. The reaction was carried out at 70° C. for 4 hours. The degree of glycosylation was measured by measuring the absorbance at 420 nm of the 96-well plate using a spectrophotometer.
하기 식의 Glycation 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420 nm에서 흡광도를 측정하였다. 하기 식으로 당화 저해율(%)을 계산하고 그 결과를 표 5에 나타내었다.The glycation experimental group of the following formula was an experimental group in which glycation was induced by adding 1M L-arginine and 1M glucose, and in order to measure the absorbance of the sample itself, only 1M L-arginine and the sample were added and the absorbance was measured at 420 nm without adding glucose. The glycation inhibition rate (%) was calculated by the following formula, and the results are shown in Table 5.
상기 표 5의 결과에서 알 수 있듯이, 분갈 추출물(실시예 1) 및 분갈화 추출물(실시예 2), 화합물 1 내지 3 모두 우수한 항당화 효과를 나타냄을 확인하였다. 또한, 피부 미백, 피부 탄력 증진 또는 주름 개선, 피부 보습 용도에 있어서도 다른 물질과 함께 상승 효과를 나타낼 것임을 기대할 수 있다.As can be seen from the results of Table 5 above, it was confirmed that the powdered extract (Example 1) and the powdered extract (Example 2), and compounds 1 to 3 all exhibit excellent anti-glycosylation effects. In addition, it can be expected that it will exhibit a synergistic effect together with other substances in skin whitening, skin elasticity enhancement or wrinkle improvement, and skin moisturizing use.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims described below and their equivalents.
Claims (15)
[화학식 1]
A cosmetic composition for skin whitening comprising a compound represented by the following formula (1) as an active ingredient.
[Formula 1]
[화학식 1]
A cosmetic composition for improving skin troubles comprising a compound represented by the following formula (1) as an active ingredient.
[Formula 1]
[화학식 1]
A cosmetic composition for enhancing skin elasticity or improving wrinkles, comprising a compound represented by the following formula (1) as an active ingredient.
[Formula 1]
[화학식 1]
A cosmetic composition for antioxidant comprising a compound represented by the following formula (1) as an active ingredient.
[Formula 1]
[화학식 1]
A cosmetic composition for skin moisturizing comprising a compound represented by the following formula (1) as an active ingredient.
[Formula 1]
[화학식 1]
For skin whitening comprising a compound represented by the following formula (1) as an active ingredient; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; or a food composition for moisturizing the skin.
[Formula 1]
[화학식 1]
For skin whitening comprising a compound represented by the following formula (1) as an active ingredient; for improving skin troubles; For improving skin elasticity or improving wrinkles; for antioxidant; Or a quasi-drug composition for skin moisturizing.
[Formula 1]
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180117817A KR102324869B1 (en) | 2018-10-02 | 2018-10-02 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
CN201910936789.4A CN110974737A (en) | 2018-10-02 | 2019-09-29 | Composition for improving skin comprising pueraria lobata extract or compound derived therefrom |
KR1020210147388A KR102425559B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210147389A KR102425562B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210150097A KR20210134589A (en) | 2018-10-02 | 2021-11-03 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180117817A KR102324869B1 (en) | 2018-10-02 | 2018-10-02 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210147388A Division KR102425559B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210147389A Division KR102425562B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210150097A Division KR20210134589A (en) | 2018-10-02 | 2021-11-03 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200038114A KR20200038114A (en) | 2020-04-10 |
KR102324869B1 true KR102324869B1 (en) | 2021-11-09 |
Family
ID=70081853
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180117817A KR102324869B1 (en) | 2018-10-02 | 2018-10-02 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210147389A KR102425562B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210147388A KR102425559B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210150097A KR20210134589A (en) | 2018-10-02 | 2021-11-03 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210147389A KR102425562B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210147388A KR102425559B1 (en) | 2018-10-02 | 2021-10-29 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
KR1020210150097A KR20210134589A (en) | 2018-10-02 | 2021-11-03 | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom |
Country Status (2)
Country | Link |
---|---|
KR (4) | KR102324869B1 (en) |
CN (1) | CN110974737A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113967174B (en) * | 2021-11-11 | 2023-10-20 | 上海澄穆生物科技有限公司 | Whitening and anti-wrinkle composition and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014065683A (en) * | 2012-09-26 | 2014-04-17 | Toyo Shinyaku Co Ltd | Anti-glycation composition |
JP6338107B2 (en) * | 2014-09-30 | 2018-06-06 | 株式会社東洋新薬 | Skin barrier function improving agent, intercellular adhesion structure formation promoter, tight junction formation promoter, and TRPV4 gene expression enhancer |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3454718B2 (en) * | 1998-06-24 | 2003-10-06 | 株式会社太田胃散 | Novel isoflavonoid compound and hangover inhibitor containing the same |
JP5204372B2 (en) * | 2004-09-24 | 2013-06-05 | 株式会社東洋新薬 | Kuzuhana-containing composition |
EP1813250A1 (en) * | 2004-10-07 | 2007-08-01 | Toyo Shinyaku Co., Ltd. | External preparation |
JP2006111541A (en) * | 2004-10-12 | 2006-04-27 | Toyo Shinyaku:Kk | Oral skin quality-improving agent containing treated material of flower of arrowroot |
CN1879616A (en) * | 2006-05-16 | 2006-12-20 | 南京大学 | Application of tectori-genin in preparation of medicine for preventing and treating liver disease and liver cancer |
CN100544716C (en) * | 2006-12-11 | 2009-09-30 | 中国人民解放军第二○八医院 | Application in iris aglycone preparation technology and the preparation Antiatherosclerosis medicine thereof |
JP2011219462A (en) * | 2010-03-25 | 2011-11-04 | Mohatsu Clinic Reve 21:Kk | Cosmetic or phamaceutical composition containing kuzu flower extract |
JP2011213600A (en) * | 2010-03-31 | 2011-10-27 | Toyo Shinyaku Co Ltd | Bleaching agent |
JP5842640B2 (en) * | 2012-01-31 | 2016-01-13 | 株式会社東洋新薬 | Phosphodiesterase 3 inhibitor |
CN103374051A (en) * | 2012-04-27 | 2013-10-30 | 黄文� | Preparation method and application of pueraria flower tectoridin |
KR20150043029A (en) * | 2013-10-14 | 2015-04-22 | 주식회사 엘지생활건강 | Composition for improving dry skin or skin barrierfunction comprising tectorigenin |
KR20150057915A (en) * | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for anti-inflammation, or skin whitening |
JP5969529B2 (en) * | 2014-03-25 | 2016-08-17 | 株式会社東洋新薬 | Anti-inflammatory agent |
JP2015127339A (en) * | 2015-03-26 | 2015-07-09 | 株式会社東洋新薬 | Composition for anti-saccharification |
CN105662906A (en) * | 2016-02-04 | 2016-06-15 | 广州军区广州总医院 | Tectorigenin sun protection skin care product |
CN105560085B (en) * | 2016-02-04 | 2019-06-21 | 广州军区广州总医院 | Iridin sunlight screening skin-protecting product |
KR102204346B1 (en) * | 2016-04-25 | 2021-01-18 | 주식회사 엘지생활건강 | Composition for relieving menopausal symptom or osteoporosis |
KR101965849B1 (en) * | 2017-03-07 | 2019-04-04 | 주식회사 엘지생활건강 | Composition for relieving menopausal symptom comprising Tectorigenin 7-O-xylosylglucoside |
CN109528741A (en) * | 2017-09-22 | 2019-03-29 | 株式会社东洋新药 | Composition comprising tectorigenin and tectorigenin glucosides |
-
2018
- 2018-10-02 KR KR1020180117817A patent/KR102324869B1/en active IP Right Grant
-
2019
- 2019-09-29 CN CN201910936789.4A patent/CN110974737A/en active Pending
-
2021
- 2021-10-29 KR KR1020210147389A patent/KR102425562B1/en active IP Right Grant
- 2021-10-29 KR KR1020210147388A patent/KR102425559B1/en active IP Right Grant
- 2021-11-03 KR KR1020210150097A patent/KR20210134589A/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014065683A (en) * | 2012-09-26 | 2014-04-17 | Toyo Shinyaku Co Ltd | Anti-glycation composition |
JP6338107B2 (en) * | 2014-09-30 | 2018-06-06 | 株式会社東洋新薬 | Skin barrier function improving agent, intercellular adhesion structure formation promoter, tight junction formation promoter, and TRPV4 gene expression enhancer |
Also Published As
Publication number | Publication date |
---|---|
KR102425562B1 (en) | 2022-08-01 |
KR20210134589A (en) | 2021-11-10 |
KR20200038114A (en) | 2020-04-10 |
KR20210134284A (en) | 2021-11-09 |
CN110974737A (en) | 2020-04-10 |
KR20210133936A (en) | 2021-11-08 |
KR102425559B1 (en) | 2022-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020532560A (en) | Cosmetic composition containing extract of Dendrobium candidam flower | |
KR102425562B1 (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR100860605B1 (en) | Cosmetic composition comprising extract of pinus strobus bark and niacinamide | |
KR100860604B1 (en) | Cosmetic composition comprising extract of pinus strobus bark | |
KR102283040B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising atractylenolide I | |
KR102639155B1 (en) | Composition for skin improvement containing valechlorine | |
KR102629000B1 (en) | Composition for skin improvement containing Salvianolic acid C | |
KR20120036417A (en) | A cosmetic composition for skin whitening comprising the extract of saccharina japonica as active ingredient | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR102356451B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising Shanzhiside methylester or a pharmaceutically acceptable salt thereof | |
KR102348149B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising parthenolide | |
KR102261933B1 (en) | Composition for improving skin conditions comprising 4-(4-Hydroxyphenyl)-2-butanone | |
KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
KR102265413B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising prim-O-glucosylcimifugin or a pharmaceutically acceptable salt thereof | |
KR102293928B1 (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising Wogonoside or a pharmaceutically acceptable salt thereof | |
KR102348148B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising dihydroartemisinin | |
KR102296938B1 (en) | Antioxidant composition comprising veronica longifolia | |
KR102526200B1 (en) | Composition for Skin Moisturizing and Whitening Comprising Decurcinol as Active Ingredient | |
KR102534818B1 (en) | Ambrosia trifida supercritical extract and its use | |
KR102601551B1 (en) | Composition for skin improvement containing liriopesides B | |
KR102644107B1 (en) | Composition for skin improvement containing vomicine | |
KR102665307B1 (en) | Composition for skin improvement containing acetylcimigenol arabinoside | |
KR102662257B1 (en) | Composition for skin improvement containing rebaudioside C | |
KR102665305B1 (en) | Composition for skin improvement containing swertisin | |
KR102636983B1 (en) | Composition for skin improvement containing isodemethylwedelolactone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
A107 | Divisional application of patent | ||
GRNT | Written decision to grant |